Travoprost
Brand names: Travatan Z, Travoprost
At a glance
- Medicare prescriptions, 2024
- 371,500
- Medicare drug cost
- $60.5M
- Average cost per prescription
- $163
- Clinicians who prescribed it
- 11,416
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
TRAVATAN Z ® (travoprost ophthalmic solution) 0.004% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
From the FDA-approved prescribing information (label dated January 2025). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Ophthalmology 70.1%
- Optometrists 23.9%
- Internal Medicine 1.9%
- Family Medicine 1.5%
- Nurse Practitioners 0.9%
- Retina Specialist 0.6%
- Geriatric Medicine 0.4%
- Physician Assistants 0.2%
- General Practice 0.2%
- Hospice & Palliative Medicine 0.0%
- Hospitalist 0.0%
- Cardiology 0.0%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions fell 61% from 2019 to 2024.
Biggest change by state since 2019
- Puerto Rico −32%
- Maryland −47%
- Oregon −48%
- Washington −49%
- Minnesota −49%
- Mississippi (smallest change) −78%
- Nevada (smallest change) −74%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
2 recalls since 2020
- May 2023 · Golden State Medical Supply Inc. · Class II
Lack of Assurance of Sterility: Tamper Evidence Seal is missing on secondary container. - Mar 2022 · Mylan Pharmaceuticals Inc · Class II
Subpotent Drug and Failed Impurities/Degradation Specifications: low out-of-specification results obtained for assay and high out-of-specification results for related substance impurities/degradation during routine stability testing.
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.